A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Psoriatic Arthritis

Incidence of treatment-emergent adverse events, Incidence of serious adverse events, Incidence of adverse events of special interest, Changes in vital signs and clinical laboratory parameters.

American College of Rheumatology (ACR)20 response: Assessed as proportion of subjects achieving ACR20 at Weeks 24, 48, and 104., ACR50 response: Assessed as proportion of subjects achieving ACR50 at Weeks 24, 48, and 104., ACR70 response: Assessed as proportion of subjects achieving ACR70 at Weeks 24, 48, and 104., Minimal disease activity (MDA): Assessed as proportion of subjects achieving MDA status at Weeks 24, 48, and 104., Psoriasis Area and Severity Index (PASI)75 (in subjects with a baseline ≥3% body surface area): Assessed as proportion of subjects achieving ≥75% improvement from baseline in PASI score at Weeks 24, 48, and 104.

No related papers found yet.

Papers published before 2002-11-01 may not appear yet. Historical indexing is in progress.